NOVARTIS PHARMACEUTICALS UK LIMITED: UK Public Sector Contracts Won & Awards
Main market: Pharmaceutical products
Official UK PPONPJTX-5182-QVLR
i
How many tenders this supplier has won.
Tenders with at least one award to it. Award records are shown too, because one framework can carry many call-offs.
i
How many different public bodies have awarded to this supplier.
Buyers named on its awards, with duplicate names merged.
i
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
i
Awards to this supplier in the last 12 months.
Award records dated in the last 12 months, against the two years before.
i
Contracts that finish in the next 18 months.
Published contracts with an end date in that window. No end date, not counted.
A likely retender, not a certain one.
i
Where this supplier has delivered.
Delivery regions published on its awarded tenders. A tender with several regions counts in each.
Where the work was, not where the company is based.
Where they wini
What kind of work is bought here.
Notices by procurement category (CPV). A notice with several categories counts in each.
i
What kind of work is bought here.
Notices by procurement category (CPV). A notice with several categories counts in each.
83 lot-level observations (81 awarded lots, 98%, plus 2 envelope awards without lot links; pending awards included) · top CPV classes
3360 Pharmaceutical products61 observations · 90% · 59 lots + 2 envelope3300 Medical equipments, pharmaceuticals and personal care products4 observations · 6% · lots3369 Various medicinal products3 observations · 4% · lotsi
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
i
What one of this supplier’s wins is usually worth.
Middle value of the same awards as the total above.
Largest published awards iThe biggest published awards. Awards to a single supplier with a published value, largest first, so you can check the totals against the notice. A repeated framework total can appear here. Open the notice to check. | Authority | Awarded | Term | Published value |
|---|---|---|---|---|
| Proprietary Drugs | eTenderwales | — | — | £8,735,000 † |
| Proprietary Drugs | Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services (on behalf of All Wales LHB's and Trusts) | — | — | £6,929,923 † |
| WT2025-07 - SECUKINUMAB 150 mg in 1mL Injection, SECUKINUMAB 300 mg in 2mL Solution for Injection | Western Health & Social Care Trust | 10 Nov 2025 | 3 yrs | £4,638,166 ≈ £1.5m/yr |
| ZOLGENSMA 2 X 10 EXP 13 VECTOR GENOMES/ML Solution for Infusion 1 Treatment Pack Pack | Belfast Health & Social Care Trust | — | — | £2,692,500 † |
| PRRT (Peptide Receptor Radionuclide Therapy) | Belfast Health & Social Care Trust | 10 Nov 2025 | 1.1 yrs | £1,820,000 ≈ £1.7m/yr |
Where they deliveri
Where this supplier has delivered.
Delivery regions published on its awarded tenders. A tender with several regions counts in each.
Where the work was, not where the company is based.
i
Where this supplier has delivered.
Delivery regions published on its awarded tenders. A tender with several regions counts in each.
Where the work was, not where the company is based.
ITL1 delivery regions on the notice · 66 of 66 awarded procedures publish one · a procedure with several regions counts in each
Bidding recordi
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
Procurement Act 2023 award notices name every bidder · 9 notices name this supplier, covering 11 lots since 20 Aug 2025 · observed bids, not an estimate
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Frameworks and DPS this supplier got onto.
Lots appointed out of lots applied for. Kept apart from contract wins because almost every compliant bidder gets a place.
i
How many public bodies this supplier has bid to.
Buyers on notices that name it as a bidder, win or lose.
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS National Generic Pharmaceuticals - Wave 16a | NHS England | appointedall 2 lots bid for | 125 | 1 Sept 2026 |
| NHS National Generics Pharmaceuticals - Supply Chain Resilience | NHS England | not appointed | 41 | 6 Jul 2026 |
| NHS National Branded Interim - 1 June 2026 | NHS England | appointed | 53 | 22 May 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | NHS England | not appointed | 118 | 26 Feb 2026 |
| NHS National Framework Agreement for Omalizumab | NHS England | appointed | 3 | 30 Dec 2025 |
| NHS National Framework for Generics Housekeeping | NHS England | appointed | 53 | 22 Dec 2025 |
| NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 | NHS England | appointed | 17 | 6 Oct 2025 |
| NHS National Framework for Transition products (Axitinib and Eltrombopag) | NHS England | appointed | 15 | 4 Sept 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | NHS England | appointed | 17 | 20 Aug 2025 |
Source: bids.details[].tenderers on Procurement Act 2023 notices (from 2025). PCR 2015 notices name no bidders, so earlier contests are invisible here. Latest ten notices shown.
Who they sell toi
Which buyers publish the most notices here.
Buyers ranked by the number of notices, duplicate names merged.
i
Which buyers publish the most notices here.
Buyers ranked by the number of notices, duplicate names merged.
Authorities named on this supplier’s published awards · ranked by distinct procedures · award records explode on framework and DPS panels
i
What kinds of public bodies buy here.
Notices by the buyer’s type as published, otherwise by its name.
- NHS & health 63% (52 awards)
- Central government 34% (28 awards)
- Type not classified 4% (3 awards)
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 19 | 28.8% | 29 | 27 Aug 2026 |
| Belfast Health & Social Care Trust | 18 | 27.3% | 18 | 8 Sept 2026 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | 5 | 7.6% | 6 | 27 Jul 2023 |
| Northern Health and Social Care Trust | 5 | 7.6% | 5 | 13 Aug 2025 |
| The NHS Commissioning Board (operating under the name of NHS England) | 3 | 4.5% | 5 | 4 Mar 2021 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) | 3 | 4.5% | 4 | 18 Aug 2025 |
| Cambridge University Hospitals NHS Foundation Trust | 3 | 4.5% | 3 | 30 Jun 2026 |
| Western Health & Social Care Trust | 2 | 3% | 2 | 10 Nov 2025 |
Share = of the 66 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
Contracts that finish in the next 18 months.
Published contracts with an end date in that window. No end date, not counted.
A likely retender, not a certain one.
i
Contracts that finish in the next 18 months.
Published contracts with an end date in that window. No end date, not counted.
A likely retender, not a certain one.
Published end dates only · 24 of 83 awards carry one · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| Utathera 7400MBq/20.5-25ml solution | 29 Sept 2026 | £17,875 |
| PRRT (Peptide Receptor Radionuclide Therapy) | 31 Dec 2026 | £1,820,000 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | 31 Jan 2027 | £22,097,000 |
| NHS National Framework for Transition products (Axitinib and Eltrombopag) | 31 Jan 2027 | £52,385,000 |
| Transitional Drugs 4 | 31 Jan 2027 | £137,717 |
| Lot 1 - CM/PHS/25/5728/01 | 31 May 2027 | £688,834,174 |
| Asciminib Tablets, 60 tablet pack, all strengths | 30 Jun 2027 | £260,000 |
| IPTACOPAN HYDROCHLORIDE MONOHYDRATE 200MG CAPSULES, 56 capsules, pack | 30 Jun 2027 | £400,000 |
| Lot 1 - CM/TNS/25/5734 | 31 Aug 2027 | £87,433,000 |
| NHS National Framework for Generics Housekeeping - Lot 2 Hospital Only products | 30 Sept 2027 | £21,562,716 |
Recent awards
Latest 30 of 83 award records naming this supplier
Data coverage & method
- Source: Find a Tender OCDS award and contract releases. An award record is one award × this supplier; a procedure can carry many (panels, call-offs).
- Market observations are awarded lots, or one envelope award when the notice publishes no lot links. Region = delivery ITL1 on the notice, not the supplier’s registered address.
- Authority type: official OCDS UK contracting-authority type when the notice publishes one; otherwise a Tenderline name/id class; otherwise “not classified”. Purchasing hubs with no published type stay unclassified.
- Published value attributable to this supplier alone: £35m across single-supplier awards, framework / DPS ceilings excluded. Coverage is partial and the figure is not turnover, so it is not shown as a headline.
- Contract end dates: published on 24 of 83 awards; 10 end within 18 months.
- Each figure’s own method and sample is behind its ; the long form is on Methodology.
- Never shown: contact details, reliability or payment scores, affiliations, predicted wins.
Identifiers consolidated into this page (18 historical Find a Tender publication identifiers)
Official notices referenced this supplier under these publication identifiers. Alias URLs are not separate pages.
Canonical page id: GB-PPON:PJTX-5182-QVLR